Construction of antibody-library to identify etiology-associated-antigen

背景和目标：核孔复合物（gp 210）的210-kDa糖蛋白抗体的存在高度指示原发性胆汁性肝硬化（PBC）。然而，抗gp 210抗体滴度监测PBC的意义仍未得到解决。方法：采用以gp 210 C端肽段为抗原的ELISA法检测71例PBC患者血清抗体滴度。结果如下：将患者分为3组：A组，其中抗gp 210滴度持续在高水平，B组，其中抗gp 210状态在熊去氧胆酸（UDCA）治疗下从阳性变为阴性，C组，其中诊断时抗gp 210抗体为阴性。A组（60%）进展为终末期肝衰竭的发生率显著高于B组（0%）和C组（4.2%）。对gp 210的持续抗体应答与界面性肝炎的严重程度密切相关。抗gp 210抗体的重要性已由日本国立医院组织肝病研究组证实。结论：血清抗gp 210-C-末端肽抗体的连续定量可用于监测UDCA的作用，并可用于早期识别终末期肝衰竭高风险患者。

Background & Aims : The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis(PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved. Methods : We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC. Results : Patients were classified into 3 groups : Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid(UDCA) therapy, Group C in whom anti-gp21 0 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan. Conclusion : The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.